Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis-Reference-Cited by-同舟云学术

Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis

Published:2024 Issue: Volume:35 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Zhu Youwen¹^ORCID,Lin Yinxin²^ORCID,Liu Kun¹^ORCID,Zhu Hong¹³^ORCID

Affiliation:

1. Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.

2. Department of General Surgery, Kailuan General Hospital, North China University of Science and Technology, Tangshan, China.

3. National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

Funder

Clinical Research Project of Xiangya Hospital

Changsha Natural Science Foundation of Hunan Provincial of China

Publisher

XMLink

Link

https://ejgo.org/pdf/10.3802/jgo.2024.35.e71

Reference40 articles.

1. Cancer statistics, 2023

2. Epithelial ovarian carcinoma

3. Ovarian Cancer

4. New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment Advances

5. National Comprehensive Cancer Network. National Comprehensive Cancer Network clinical practice guidelines in oncology. NCCN guidelines®: ovarian cancer, version 2 [Internet]. Plymouth Meeting, PA. National Comprehensive Cancer Network. 2023. cited 2022 Jun 2. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy;Journal of Ovarian Research;2024-08-08